13F reference period
Q3 2026
Security Snapshot
Aktis Oncology, Inc. - Common Stock (AKTS) Institutional Ownership
CUSIP: 01021M104
13F Institutional Holders and Ownership History from Q1 2026 to Q3 2026
Institutions Reporting
48
Shares (Excl. Options)
6.94M
Full value: 6,941,277 · shares · 30 Sep 2026Price
$19.47
The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- AKTS on Nasdaq
- All holders as of 30 Sep 2026
- Q3 2026
- Total 13F shares
- 6,941,277
- Total 13F value
- $135,194,600
- Portfolio coverage rank
- 0%
- Share change
- +2,489,394
- Value change
- +$46,701,529
- Number of holders
- 48
- Shares outstanding
- 53,432,253
- SEC-reported price per share
- $17.34
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- AKTS - Aktis Oncology, Inc. - Common Stock is tracked under CUSIP 01021M104.
- 48 institutions reported positions in Q3 2026.
- 2 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 113 to 48 between Q2 2026 and Q3 2026.
- SEC-reported value moved from to
$1.1B
Full value: $1,101,283,078 · USD · 30 Jun 2026.$135.19M
Full value: $135,194,600 · USD · 30 Sep 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 48 institutions filings for Q3 2026.
Security key
01021M104
13F reference period
Q3 2026
13F holders
48
13D/G owners
2
CIK / CUSIP context first
Open Q3 2026 holders
AKTS full holder history
Aktis Oncology, Inc. SEC filings
Aktis Oncology, Inc. company facts
Aktis Oncology, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 01021M104:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
2
Security
AKTS
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| VV Manager II, LLC | 11% | 5,831,315 | Helen Kim | 12 Jan 2026 | ||||
| EcoR1 Capital, LLC | 9.1% | 4,862,335 | Oleg Nodelman | 12 Jan 2026 |
As of 30 Sep 2026,
48
institutional investors reported holding
shares of
Aktis Oncology, Inc. - Common Stock (AKTS).
This represents
13%
of the company’s total
outstanding shares.
6.94M
Full value: 6,941,277 · shares · 30 Sep 202653.43M
Full value: 53,432,253 · shares · Stored outstanding share count13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
13%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | 2.2% | 1,180,925 | +45% | 0% | $22,992,610 |
| EVENTIDE ASSET MANAGEMENT, LLC | 2% | 1,065,000 | +110% | 0.29% | $20,735,550 |
| STATE STREET CORP | 2% | 1,050,480 | +117% | 0% | $20,452,846 |
| Merck & Co., Inc. | 1.8% | 952,844 | 0% | 2.3% | $18,551,873 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.3% | 690,427 | +33% | 0% | $13,445,777 |
| Affinity Asset Advisors, LLC | 0.66% | 350,000 | 0.39% | $6,814,500 | |
| TD ASSET MANAGEMENT INC | 0.38% | 203,494 | +92% | 0% | $4,006,797 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 0.37% | 198,386 | +37% | 0% | $3,862,575 |
| VANGUARD FIDUCIARY TRUST CO | 0.34% | 183,780 | +37% | 0% | $3,578,197 |
| Mirador Capital Partners LP | 0.25% | 133,558 | +233% | 0.3% | $2,600,374 |
| Jump Financial, LLC | 0.21% | 112,187 | +242% | 0.02% | $2,184,281 |
| Quantinno Capital Management LP | 0.2% | 109,075 | +133% | 0% | $2,123,690 |
| MORGAN STANLEY | 0.17% | 91,569 | +46% | 0% | $1,782,849 |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | 0.15% | 80,065 | +67% | 0% | $1,558,866 |
| POLEN CAPITAL MANAGEMENT LLC | 0.14% | 72,795 | +15% | 0.02% | $1,417,319 |
| BNP PARIBAS FINANCIAL MARKETS | 0.13% | 70,816 | 0% | $1,378,788 | |
| MARSHALL WACE, LLP | 0.13% | 69,158 | 0% | $1,346,507 | |
| Tidal Investments LLC | 0.12% | 65,989 | +16% | 0% | $1,284,806 |
| Quadrature Capital Ltd | 0.12% | 61,695 | 0.01% | $1,201,202 | |
| RENAISSANCE TECHNOLOGIES LLC | 0.06% | 30,539 | -68% | 0% | $594,594 |
| RAYMOND JAMES FINANCIAL INC | 0.06% | 30,449 | -40% | 0% | $592,842 |
| DEUTSCHE BANK AG\ | 0.05% | 24,350 | +16% | 0% | $474,095 |
| Rafferty Asset Management, LLC | 0.04% | 22,132 | 0% | $430,910 | |
| NLB Skladi, upravljanje premozenja, d.o.o. | 0.03% | 15,000 | 0.01% | $292,050 | |
| Virtus Investment Advisers, LLC | 0.03% | 14,470 | -3% | 0.06% | $281,731 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
3
Headline period
Q3 2026
Rows shown
1-3 of 3